NCT00311870已完成4 期
Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- change in glomerular filtration rate from study start to study end
研究概览
简要总结
The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diabetic nephropathy, type 1 diabetes, hypertension
排除标准
- •child bearing potential, non-diabetic kidney disease, malignancy
结局指标
主要结局
change in glomerular filtration rate from study start to study end
次要结局
- change in urinary albumin excretion rate
- blood pressure response
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Study on Renoprotective effect of cilnidipine and amlodipine along with telmisartan in patients with type-2 diabetes and hypertensioCTRI/2024/04/065259Sri Ramaswamy Memorial
招募中
不适用
To Compare the renoprotective effect of sitagliptin and vildagliptin for patient with type 2 diabetic nephropathyDiabetic nephropathyJPRN-UMIN000011678Machida Municipal Hospital60
已完成
不适用
Evaluation of renoprotective and hypotensive effects by combined use of irbesartan and amlodipine besilate in elderly patients with hypertension.HypertensionJPRN-UMIN000008841Kanazawa Medical University30
已完成
不适用
Renoprotective effect of Calcium channel blocker or Diuretics treatment with Renin-Angiotensin system(RAS) inhibitor in hypertensive patients with chronic kidney disease(CKD) (CD Study)Hypertensive patients with CKD under the treatment of the inhibitor of the renin-angiotensin system(RAS)JPRN-UMIN000004304iigata University300
进行中（未招募）
1 期
This study aims to investigate the potential beneficial effects on the kidney of a new medication called Dapagliflozin in type 2 diabetic patients.MedDRA version: 20.1 Level: PT Classification code 10061835 Term: Diabetic nephropathy System Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersDiabetic NephropathyEUCTR2013-004042-42-GBKing’s College London40